Scheen, André J.
Article History
First Online: 21 June 2019
Compliance with Ethical Standards
:
: No conflicts of interest are directly relevant to the content of this manuscript.A.J. Scheen has received lecturer/advisor fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, NovoNordisk, Sanofi, and Servier. He also worked as clinical investigator in the three cardiovascular outcome trials with SGLT2 inhibitors, EMPA-REG-OUTCOME, CANVAS-R, and DECLARE-TIMI 58.
: This article does not contain any studies with human or animal subjects performed by the author.